SCHEMBL23218410

SCHEMBL23218410

CCOC(=O)Cc1ccc(OC)cc1OCc1coc2c(Br)cc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.39
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MAOB P27338 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PTPN1 P18031 1/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852974 1.00 PTGS2 (0.39) PTGS2MAPTL3MBTL1MAOBTSHR
SCHEMBL28736121 0.88 MAPT (0.37) PTGS2MAPTL3MBTL1TSHRGAA
SCHEMBL29853095 0.88 PTGS2 (0.38) PTGS2MAPTL3MBTL1TSHRHTT
SCHEMBL23218636 0.88 PTGS2 (0.38) PTGS2MAPTL3MBTL1TSHRHTT
SCHEMBL29591267 0.87 TBXAS1 (0.40) MAPTMAOBGAAMEN1KMT2A
SCHEMBL23219098 0.87 TBXAS1 (0.40) MAPTMAOBGAAMEN1KMT2A
SCHEMBL23218673 0.85 PTGS2 (0.37) PTGS2MAPTL3MBTL1TSHRHTT
SCHEMBL29592763 0.85 PTGS2 (0.37) PTGS2MAPTL3MBTL1TSHRHTT
SCHEMBL29853214 0.85 PTGS2 (0.37) PTGS2MAPTL3MBTL1TSHRHTT
SCHEMBL23218855 0.85 MAPT (0.40) MAPTL3MBTL1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGS2 1208/4885MAPT 4793/4885L3MBTL1 4262/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGS2 2338/4885MAPT 3561/4885L3MBTL1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.